Arcus Biosciences Income Before Tax Over Time
| RCUS Stock | USD 17.96 0.54 3.10% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Arcus Biosciences Performance and Arcus Biosciences Correlation. Arcus |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcus Biosciences. If investors know Arcus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arcus Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.19) | Revenue Per Share 3.058 | Quarterly Revenue Growth 0.5 | Return On Assets (0.15) | Return On Equity (0.50) |
The market value of Arcus Biosciences is measured differently than its book value, which is the value of Arcus that is recorded on the company's balance sheet. Investors also form their own opinion of Arcus Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Arcus Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcus Biosciences' market value can be influenced by many factors that don't directly affect Arcus Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arcus Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arcus Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcus Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Income Before Tax Analysis
Compare Arcus Biosciences and related stocks such as Cullinan Oncology LLC, Annexon, and Structure Therapeutics Income Before Tax Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CGEM | (704.7 K) | (704.7 K) | (704.7 K) | (704.7 K) | (130.5 K) | (109.5 K) | (316.7 K) | (14.2 M) | (14.2 M) | (21.7 M) | (59.5 M) | (67.5 M) | 151.3 M | (169.2 M) | (160.8 M) |
| ANNX | (18.7 M) | (18.7 M) | (18.7 M) | (18.7 M) | (18.7 M) | (18.7 M) | (18.7 M) | (18.7 M) | (18.3 M) | (37.2 M) | (63.4 M) | (130.3 M) | (141.9 M) | (134.2 M) | (127.5 M) |
| GPCR | (15.7 K) | (15.7 K) | (15.7 K) | (15.7 K) | (15.7 K) | (15.7 K) | (15.7 K) | (15.7 K) | (15.7 K) | (15.7 K) | (15.7 K) | (37.8 K) | (51.3 M) | (89.4 M) | (84.9 M) |
| RLAY | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (48.8 M) | (75.3 M) | (52.4 M) | (363.9 M) | (290.5 M) | (342 M) | (324.9 M) |
| DAWN | (17 M) | (17 M) | (17 M) | (17 M) | (17 M) | (17 M) | (17 M) | (17 M) | (17 M) | (17 M) | (43.8 M) | (72.8 M) | (142.2 M) | (188.9 M) | (179.5 M) |
| ABOS | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.3 M) | (100.6 M) | (42.9 M) | (52.4 M) | (55 M) |
| XFOR | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (23 M) | (33.9 M) | (43 M) | (52.8 M) | (62 M) | (88.7 M) | (93.8 M) | (101.1 M) | (96 M) |
| INZY | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (19.7 M) | (56.4 M) | (56.6 M) | (67.1 M) | (71.2 M) | (74.7 M) |
| PTCT | 28.6 M | 28.6 M | (26.2 M) | (51.6 M) | (98.4 M) | (170 M) | (141.5 M) | (77.7 M) | (128.1 M) | (239.9 M) | (402.9 M) | (518.3 M) | (587.5 M) | (696.1 M) | (661.3 M) |
| BPMC | (20.9 M) | (20.9 M) | (20.9 M) | (20.9 M) | (40.3 M) | (52.8 M) | (72.5 M) | (148.1 M) | (236.6 M) | (347.7 M) | 314.9 M | (641.1 M) | (552.3 M) | (506 M) | (480.7 M) |
| KRYS | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (7.9 M) | (10.9 M) | (19.1 M) | (32.2 M) | (69.6 M) | (140 M) | 12.9 M | 13.5 M |
| MDGL | (54.4 M) | (47.4 M) | (62.8 M) | (90.2 M) | (86.2 M) | (68.7 M) | (26.4 M) | (31.2 M) | (32.8 M) | (83.9 M) | (202.2 M) | (241.8 M) | (295.4 M) | (373.6 M) | (354.9 M) |
| IMMX | (952.3 K) | (952.3 K) | (952.3 K) | (952.3 K) | (952.3 K) | (952.3 K) | (952.3 K) | (952.3 K) | (952.3 K) | (952.3 K) | (1.1 M) | (24.4 M) | (8.2 M) | (15.6 M) | (16.3 M) |
| CNSP | (219.4 K) | (219.4 K) | (219.4 K) | (219.4 K) | (219.4 K) | (219.4 K) | (219.4 K) | (219.4 K) | (7.4 M) | (3.9 M) | (9.5 M) | (14 M) | (15.3 M) | (18.9 M) | (17.9 M) |
| HEPA | (843 K) | (843 K) | (843 K) | (5.3 M) | (5.3 M) | (14.3 M) | (17 M) | (16.8 M) | (10 M) | (7.9 M) | (20.3 M) | (32.7 M) | (45.1 M) | (49.3 M) | (46.9 M) |
| APLS | (4 M) | (4 M) | (4 M) | (4 M) | (11.2 M) | (46.5 M) | (27.1 M) | (51 M) | (127.5 M) | (304.7 M) | (343 M) | (746 M) | (651.5 M) | (526.5 M) | (500.2 M) |
| ITOS | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (22.3 M) | (38.1 M) | 256.5 M | 148.7 M | (109 M) | (103.6 M) |
| TCRX | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (26.1 M) | (48.6 M) | (66.2 M) | (89.2 M) | (84.8 M) |
Arcus Biosciences and related stocks such as Cullinan Oncology LLC, Annexon, and Structure Therapeutics Income Before Tax description
Income Before Tax which can also be referred as pre-tax income is reported on Arcus Biosciences income statement and is an important metric when analyzing Arcus Biosciences profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.My Equities
My Current Equities and Potential Positions
| Arcus Biosciences | RCUS |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | New York Stock Exchange |
USD 17.96
Additional Tools for Arcus Stock Analysis
When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.